U.S. market Closed. Opens in 1 day 8 hours 59 minutes

APRE | Aprea Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.02 - 3.24
52 Week Range 2.1500 - 8.85
Beta 1.41
Implied Volatility 506.85%
IV Rank 100.00%
Day's Volume 6,751
Average Volume 27,115
Shares Outstanding 5,434,900
Market Cap 16,576,445
Sector Healthcare
Industry Biotechnology
IPO Date 2019-10-03
Valuation
Profitability
Growth
Health
P/E Ratio -1.09
Forward P/E Ratio N/A
EPS -2.80
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 7
Country USA
Website APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
*Chart delayed
Analyzing fundamentals for APRE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see APRE Fundamentals page.

Watching at APRE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on APRE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙